Clinical Trials

55 enrolled

Disease, Lung Neoplasms, Neoplasms, Recurrence

NCT04319224 2024-05-30

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Phase 1/2 Terminated

4 enrolled 10 charts

Neoplasms

NCT04892043 2024-02-23

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1 Terminated

5 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04894994 2023-12-05

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Phase 2 Terminated

6 enrolled 10 charts

Neoplasms

NCT02467361 2023-11-14

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

104 enrolled

Neoplasms

NCT02904226 2023-07-03

ICONIC

Phase 1/2 Completed

242 enrolled 29 charts

Neoplasms

NCT04084951 2023-04-14

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

30 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

80 enrolled 33 charts

DermatologicGastrointestinalGenitourinaryThoracic

Neoplasms

NCT04311710 2023-02-24

CheckMate 76U

Phase 1 Terminated

21 enrolled

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Completed

337 enrolled 42 charts

Neoplasms

NCT03989362 2022-09-10

EMERGE

Phase 2 Completed

61 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03525795 2022-05-18

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

24 enrolled

Neoplasms

NCT03271047 2022-01-04

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Phase 2 Completed

75 enrolled 17 charts

Neoplasms

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

Unknown

130 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03026166 2020-07-17

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Terminated

42 enrolled 15 charts

Neoplasms, Small Cell Lung Carcinoma

NCT04169867 2019-11-20

Polish Microbiome Map

Unknown

1,160 enrolled

Dermatologic

Melanoma, Neoplasms

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

BreastDermatologicHead & NeckLymphoid

80 enrolled

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01750580 2015-07-22

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

22 enrolled